At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 155 enrolled
Drug / intervention
Nadolol +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy and Safety of Βeta-adrenoceptor Inverse Agonist and Biased Ligand, Nadolol, In Smoking Cessation of Patients With Chronic Cough With or Without Airflow Obstruction
In Brief
A Phase 2 clinical trial evaluating Nadolol and Placebo for Smoking Cessation. Completed, enrolled 155 participants across 4 sites.
Detailed Summary
To test the hypothesis that treatment with the inverse agonist nadolol will improve smoking cessation in patients with chronic cough associated with long-term smoking, with or without airflow obstruction, including those with established chronic obstructive pulmonary disease (COPD) (chronic bronchitis dominant) or non-obstructive chronic bronchitis (NCB), compared to placebo and standard of care, while undergoing a validated smoking cessation program.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSmoking Cessation
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedApr 2013
Enrollment StartMar 2014
Primary CompletionJun 2015
Study CompletionAug 2015
TodayJul 2026
First PostedApr 5, 2013
Enrollment StartMar 1, 2014
Primary CompletionJun 1, 2015
Study CompletionAug 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 13.2 years ago
Interventions
Nadololdrug
Placebodrug